Literature DB >> 14764586

Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate.

Philippe Gervois1, Robert Kleemann, Antoine Pilon, Frédéric Percevault, Wolfgang Koenig, Bart Staels, Teake Kooistra.   

Abstract

The peroxisome proliferator-activated receptor alpha (PPARalpha), which is highly expressed in liver, plays key roles in lipid metabolism and inflammation. Interleukin-6 (IL-6) is the principal inducer of acute phase response (APR) gene expression. In the present study, we demonstrate that chronic treatment with the PPARalpha agonist fenofibrate fully prevents the IL-6-induced APR gene expression in wild-type but not in PPARalpha-deficient mice. PPARalpha prevents the IL-6-induced expression of the positive APR genes fibrinogen-alpha, -beta, -gamma, haptoglobulin, and serum amyloid A and the IL-6-induced suppression of the negative APR gene, major urinary protein. Furthermore, the effect of PPARalpha on the APR gene expression does not simply consist in a delayed systemic response to IL-6 but occurs directly at the transcriptional level. This global suppression of acute phase gene transcription may be explained by two PPARalpha-dependent in vivo effects: 1) PPARalpha activation results in the down-regulation of the IL-6 receptor components gp80 and gp130 in the liver, thereby reducing the phosphorylation and activation of the downstream transcription factors STAT3 and c-Jun that transduce the IL-6 signal; and 2) PPARalpha reduces the basal expression of the transcription factors CCAAT enhancer-binding protein-alpha, -beta, -delta, which are responsible for immediate and maintained transcription of APR genes. A similar global effect of fenofibrate on acute phase protein expression is observed in hyperlipidemic patients chronically treated with fenofibrate, which displayed decreased plasma concentrations of the positive APR proteins fibrinogen, C-reactive protein, serum amyloid A, plasminogen, and alpha2-macroglobulin and increased plasma concentrations of the negative APR albumin, underlining the clinical significance of our findings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764586     DOI: 10.1074/jbc.M400346200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  68 in total

1.  Proteome Dynamics Reveals Pro-Inflammatory Remodeling of Plasma Proteome in a Mouse Model of NAFLD.

Authors:  Ling Li; Gurkan Bebek; Stephen F Previs; Jonathan D Smith; Rovshan G Sadygov; Arthur J McCullough; Belinda Willard; Takhar Kasumov
Journal:  J Proteome Res       Date:  2016-08-05       Impact factor: 4.466

Review 2.  PPARs and molecular mechanisms of transrepression.

Authors:  Mercedes Ricote; Christopher K Glass
Journal:  Biochim Biophys Acta       Date:  2007-03-12

3.  Gene modulation associated with inhibition of liver regeneration in hepatitis B virus X transgenic mice.

Authors:  Malgorzata Sidorkiewicz; Jean-Philippe Jais; Guilherme Tralhao; Serban Morosan; Carlo Giannini; Nicolas Brezillon; Patrick Soussan; Oona Delpuech; Dina Kremsdorf
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

4.  Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.

Authors:  Joshua F Heiber; Glen N Barber
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

Review 5.  The interaction between HCV and nuclear receptor-mediated pathways.

Authors:  Zoe Raglow; Carly Thoma-Perry; Richard Gilroy; Yu-Jui Yvonne Wan
Journal:  Pharmacol Ther       Date:  2011-05-18       Impact factor: 12.310

6.  IL-6-mediated signaling pathways limit Chlamydia muridarum infection and exacerbate its pathogenicity in the mouse genital tract.

Authors:  Xin Sun; Qi Tian; Luying Wang; Min Xue; Guangming Zhong
Journal:  Microbes Infect       Date:  2017-08-31       Impact factor: 2.700

Review 7.  Pleiotropic effects of fibrates.

Authors:  Giulia Chinetti-Gbaguidi; Jean Charles Fruchart; Bart Staels
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

8.  PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-kappaB and AP-1 pathways.

Authors:  Sriram Ramanan; Mitra Kooshki; Weiling Zhao; Fang-Chi Hsu; Mike E Robbins
Journal:  Free Radic Biol Med       Date:  2008-09-17       Impact factor: 7.376

9.  Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors.

Authors:  S Mandard; R Stienstra; P Escher; N S Tan; I Kim; F J Gonzalez; W Wahli; B Desvergne; M Müller; S Kersten
Journal:  Cell Mol Life Sci       Date:  2007-05       Impact factor: 9.261

10.  Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk?

Authors:  Ahmad Aljada; Kshitij Ashwin Shah; Shaker A Mousa
Journal:  PPAR Res       Date:  2009-08-19       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.